Related Experiment Video

Updated: Sep 15, 2026

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells
09:40

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells

Published on: December 4, 2007

PG13 packaging cells produce recombinant retroviruses carrying a diphtheria toxin mutant which kills cancer cells

Jian Qiao1, Manuel Caruso

  • 1Le Centre de Recherche en Cancérologie de l'Université Laval, L'Hôtel Dieu de Québec, Centre Hospitalier Universitaire de Québec, Québec G1R 2J6, Canada.

Journal of Virology
|June 20, 2002
PubMed

Insights

Researchers found that PG13 packaging cells resist diphtheria toxin A (DT-A) mutant toxicity. This resistance allows for the production of recombinant viruses, enabling effective killing of human tumor cells for suicide gene therapy.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Virology

Background:

  • Suicide gene therapy development using toxic gene products like diphtheria toxin A (DT-A) is challenging due to difficulties in engineering recombinant viruses.
  • Low DT-A expression in virus producer cells inhibits recombinant virus production, hindering therapeutic applications.

Purpose of the Study:

  • To investigate the natural resistance of packaging cell lines to DT-A toxicity.
  • To determine if resistant packaging cells can be used to produce functional recombinant viruses for cancer therapy.

Main Methods:

  • Analysis of natural resistance of packaging cell lines (PG13 and PA317) to a DT-A mutant (H21G).
  • Production of recombinant H21G virus using PG13 packaging cells.
  • Evaluation of the efficacy of the recombinant H21G virus in killing various human tumor cells.

Main Results:

  • PG13 and PA317 packaging cell lines demonstrated resistance to the H21G DT-A mutant.
  • PG13 cells successfully produced recombinant H21G virus.
  • The produced recombinant H21G virus exhibited efficient killing of diverse human tumor cell types.

Conclusions:

  • PG13 packaging cells are resistant to a specific DT-A mutant, overcoming a key hurdle in recombinant virus production.
  • This finding establishes PG13 cells as a valuable platform for developing DT-A-based suicide gene therapy.
  • The developed system shows significant potential for targeting and eliminating human tumors through gene therapy.

More Related Videos

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells16:04

A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells

Published on: June 19, 2013

Related Concept Videos

Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...